Syndecan 1 may slow the progression of subclinical atherosclerosis in patients with ankylosing spondylitis

References

• Reveille JD, Arnett FC. Spondyloarthritis: update on pathogenesis and management. Am J Med. 2005 Jun;118(6):592–6. doi:10.1016/j.amjmed.2005.01.001. PMID: 15922688.
   PubMed Web of Science ®Google Scholar
• Khan MA. Update on spondyloarthropathies. Ann Intern Med. 2002 Jun 18;136(12):896–907. doi:10.7326/0003-4819-136-12-200206180-00011. PMID: 12069564.
   PubMed Web of Science ®Google Scholar
• Tsui FW, Tsui HW, Akram A, Haroon N, Inman RD. The genetic basis of ankylosing spondylitis: new insights into disease pathogenesis. Appl Clin Genet. 2014 May 22; 7: 105–15. doi: 10.2147/TACG.S37325. PMID: 24971029.
   PubMedGoogle Scholar
• Zhang S, Peng L, Li Q, Zhao J, Xu D, Zhao J, Wang Q, Li M, Zhang W, Tian X, et al. Spectrum of spondyloarthritis among Chinese populations. Curr Rheumatol Rep. 2022 Aug;24(8):247–58. doi:10.1007/s11926-022-01079-1. Epub 2022 Jul 13. PMID: 35829981.
   PubMed Web of Science ®Google Scholar
• Maggio D, Grossbach A, Gibbs D, Moranville R, Toop N, Xu D, Viljoen S. Spinal deformity correction in ankylosing spondylitis. Surg Neurol Int. 2022 Apr 8; 13: 138. doi: 10.25259/SNI_254_2022. PMID: 35509590.
   PubMedGoogle Scholar
• Bhattad PB, Kulkarni M, Patel PD, Roumia M. Cardiovascular morbidity in ankylosing spondylitis: a focus on inflammatory cardiac disease. Cureus. 2022 Jun 3;14(6):e25633. doi:10.7759/cureus.25633. PMID: 35795520.
   PubMed Web of Science ®Google Scholar
• Mauro D, Thomas R, Guggino G, Lories R, Brown MA, Ciccia F. Ankylosing spondylitis: an autoimmune or autoinflammatory disease? Nat Rev Rheumatol. 2021 Jul;17(7):387–404. doi:10.1038/s41584-021-00625-y.
   PubMed Web of Science ®Google Scholar
• Mandour M, Chen S, van de Sande Mgh. The role of the IL-23/IL-17 axis in disease initiation in spondyloarthritis: lessons learned from animal models. Front Immunol. 2021 Jun 29; 12: 618581. doi: 10.3389/fimmu.2021.618581. PMID: 34267743.
   PubMed Web of Science ®Google Scholar
• El Maghraoui A. Extra-articular manifestations of ankylosing spondylitis: prevalence, characteristics and therapeutic implications. Eur J Intern Med. 2011 Dec;22(6):554–60. doi:10.1016/j.ejim.2011.06.006.
   PubMed Web of Science ®Google Scholar
• El Mathari S, van der Wal A, Raterman H, Kluin J . Mitral valve disease in ankylosing spondylitis: an autoimmune disease manifestation? A case report. Eur Heart J Case Rep. 2022 Aug 1;6(8):ytac322. doi:10.1093/ehjcr/ytac322. PMID: 36072913.
   PubMedGoogle Scholar
• Divecha H, Sattar N, Rumley A, Cherry L, Lowe GD, Sturrock R. Cardiovascular risk parameters in men with ankylosing spondylitis in comparison with non-inflammatory control subjects: relevance of systemic inflammation. Clin Sci (Lond). 2005 Aug;109(2):171–76. doi:10.1042/CS20040326. PMID: 15801904.
   PubMed Web of Science ®Google Scholar
• Balčiūnaitė A, Budrikis A, Rumbinaitė E, Sabaliauskienė J, Patamsytė V, Lesauskaitė V. Ankylosing spondyloarthritis resulting severe aortic insufficiency and aortitis: exacerbation of ankylosing spondyloarthritis and stenosis of the main left coronary artery after mechanical aortic valve implantation with cardiopulmonary bypass. Case Rep Rheumatol. 2020 Jan 3;2020:9538527. doi:10.1155/2020/9538527. PMID: 31984147.
   PubMedGoogle Scholar
• Fernández-Alvarez V, Linares Sánchez M, López Alvarez F, Suárez Nieto C, Mäkitie AA, Olsen KD, Ferlito A. Evaluation of intima-media thickness and arterial stiffness as early ultrasound biomarkers of carotid artery atherosclerosis. Cardiol Ther. 2022 Jun;11(2):231–47. doi:10.1007/s40119-022-00261-x. Epub 2022 Apr 1. PMID: 35362868.
   PubMed Web of Science ®Google Scholar
• Aydoğan Baykara R, Küçük A, Tuzcu A, Tuzcu G, Cüre E, Uslu AU, Omma A. The relationship of serum visfatin levels with clinical parameters, flow-mediated dilation, and carotid intima-media thickness in patients with ankylosing spondylitis. Turk J Med Sci. 2021 Aug 30;51(4):1865–74. doi:10.3906/sag-2012-351. PMID: 33754654.
   PubMed Web of Science ®Google Scholar
• Chakravarti R, Adams JC. Comparative genomics of the syndecans defines an ancestral genomic context associated with matrilins in vertebrates. BMC Genomics. 2006 Apr 18;7(1):83. doi:10.1186/1471-2164-7-83. PMID: 16620374.
   PubMedGoogle Scholar
• Altemeier WA, Schlesinger SY, Buell CA, Brauer R, Rapraeger AC, Parks WC, Chen P. Transmembrane and extracellular domains of syndecan-1 have distinct functions in regulating lung epithelial migration and adhesion. J Biol Chem. 2012 Oct 12;287(42):34927–35. doi:10.1074/jbc.M112.376814.
   PubMed Web of Science ®Google Scholar
• Teng YH, Aquino RS, Park PW. Molecular functions of syndecan-1 in disease. Matrix Biol. 2012 Jan;31(1):3–16. doi:10.1016/j.matbio.2011.10.001. Epub 2011 Oct 18. PMID: 22033227.
   PubMed Web of Science ®Google Scholar
• Vanhoutte D, Schellings MW, Götte M, Swinnen M, Herias V, Wild MK, Vestweber D, Chorianopoulos E, Cortés V, Rigotti A, et al. Increased expression of syndecan-1 protects against cardiac dilatation and dysfunction after myocardial infarction. Circulation. 2007 Jan 30;115(4):475–82. doi:10.1161/CIRCULATIONAHA.106.644609
   PubMed Web of Science ®Google Scholar
• Patterson AM, Cartwright A, David G, Fitzgerald O, Bresnihan B, Ashton BA, Middleton J. Differential expression of syndecans and glypicans in chronically inflamed synovium. Ann Rheum Dis. 2008 May;67(5):592–601. doi:10.1136/ard.2006.063875.
   PubMed Web of Science ®Google Scholar
• Angsana J, Chen J, Smith S, Xiao J, Wen J, Liu L, Haller CA, Chaikof EL. Syndecan-1 modulates the motility and resolution responses of macrophages. Arterioscler Thromb Vasc Biol. 2015 Feb;35(2):332–40. doi:10.1161/ATVBAHA.114.304720.
   PubMed Web of Science ®Google Scholar
• Ward MM, Deodhar A, Gensler LS, Dubreuil M, Yu D, Khan MA, Haroon N, Borenstein D, Wang R, Biehl A, et al. Update of the American college of rheumatology/spondylitis association of America/spondyloarthritis research and treatment network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheumatol. 2019 Oct;71(10):1599–613. doi:10.1002/art.41042.
   PubMed Web of Science ®Google Scholar
• Eriksson JK, Jacobsson L, Bengtsson K, Askling J. Is ankylosing spondylitis a risk factor for cardiovascular disease, and how do these risks compare with those in rheumatoid arthritis? Ann Rheum Dis. 2017 Feb;76(2):364–70. doi:10.1136/annrheumdis-2016-209315.
   PubMed Web of Science ®Google Scholar
• González Mazón I, Rueda-Gotor J, Ferraz-Amaro I, Genre F, Corrales A, Calvo Rio V, Palmou Fontana N, Portilla V, Llorca J, Mata C, et al. Subclinical atherosclerotic disease in ankylosing spondylitis and non-radiographic axial spondyloarthritis. A multicenter study on 806 patients. Semin Arthritis Rheum. 2021 Apr;51(2):395–403. doi:10.1016/j.semarthrit.2021.02.003.
   PubMed Web of Science ®Google Scholar
• Schinocca C, Rizzo C, Fasano S, Grasso G, La Barbera L, Ciccia F, Guggino G. Role of the IL-23/IL-17 pathway in rheumatic diseases: an overview. Front Immunol. 2021 Feb 22;12:637829. doi: 10.3389/fimmu.2021.637829.
   PubMed Web of Science ®Google Scholar
• Łosińska K, Korkosz M, Kwaśny-Krochin B. 2019. Endothelial dysfunction in patients with ankylosing spondylitis. Reumatologia. 57(2):100–05. doi:10.5114/reum.2019.84815
   PubMedGoogle Scholar
• Cure E, Icli A, Uslu AU, Sakiz D, Cure MC, Baykara RA, Yavuz F, Arslan S, Kucuk A. Atherogenic index of plasma: a useful marker for subclinical atherosclerosis in ankylosing spondylitis: AIP associate with cIMT in AS. Clin Rheumatol. 2018 May;37(5):1273–80. doi:10.1007/s10067-018-4027-0.
   PubMed Web of Science ®Google Scholar
• Verma I, Krishan P, Syngle A. Predictors of atherosclerosis in ankylosing spondylitis. Rheumatol Ther. 2015 Dec;2(2):173–82. doi:10.1007/s40744-015-0017-8.
   PubMedGoogle Scholar
• Gupta N, Saigal R, Goyal L, Agrawal A, Bhargava R, Agrawal A. Carotid intima media thickness as a marker of atherosclerosis in ankylosing spondylitis. Int J Rheumatol. 2014;2014:839135. 10.1155/2014/839135.
   PubMedGoogle Scholar
• Chignalia AZ, Yetimakman F, Christiaans SC, Unal S, Bayrakci B, Wagener BM, Russell RT, Kerby JD, Pittet JF, Dull RO. The glycocalyx And Trauma: a review. Shock. 2016 Apr;45(4):338–48. doi:10.1097/SHK.0000000000000513.
   PubMed Web of Science ®Google Scholar
• Uchimido R, Schmidt EP, Shapiro NI. The glycocalyx: a novel diagnostic and therapeutic target in sepsis. Crit Care. 2019 Jan 17;23(1):16. doi:10.1186/s13054-018-2292-6.
   PubMedGoogle Scholar
• Lei J, Xue SN, Wu W, Zhou SX, Zhang YL, Yuan GY, Wang JF. Increased level of soluble syndecan-1 in serum correlates with myocardial expression in a rat model of myocardial infarction. Mol Cell Biochem. 2012 Jan;359(1–2):177–82. doi:10.1007/s11010-011-1012-1.
   PubMed Web of Science ®Google Scholar
• Nemoto T et al . (2020). Endothelial glycocalyx and severity and vulnerability of coronary plaque in patients with coronary artery disease. Atherosclerosis, 302 1–7. 10.1016/j.atherosclerosis.2020.04.014
   PubMed Web of Science ®Google Scholar
• Miranda CH, de Carvalho Borges M, Schmidt A, Marin-Neto JA, Pazin-Filho A. Evaluation of the endothelial glycocalyx damage in patients with acute coronary syndrome. Atherosclerosis. 2016Apr;247: 184–88.10.1016/j.atherosclerosis.2016.02.023.
   PubMed Web of Science ®Google Scholar
• Nguyen TH, Liu S, Ong GJ, Stafford I, Frenneaux MP, Horowitz JD. Glycocalyx shedding is markedly increased during the acute phase of Takotsubo cardiomyopathy. Int J Cardiol. 2017 Sep 15;243:296–99. doi: 10.1016/j.ijcard.2017.04.085.
   PubMed Web of Science ®Google Scholar
• Wernly B, Fuernau G, Masyuk M, Muessig JM, Pfeiler S, Bruno RR, Desch S, Muench P, Lichtenauer M, Kelm M, et al. Syndecan-1 predicts outcome in patients with st-segment elevation infarction independent from infarct-related myocardial injury. Sci Rep. 2019 Dec 4;9(1):18367. doi:10.1038/s41598-019-54937-x.
   PubMedGoogle Scholar
• Schmidt EP, Yang Y, Janssen WJ, Gandjeva A, Perez MJ, Barthel L, Zemans RL, Bowman JC, Koyanagi DE, Yunt ZX, et al. The pulmonary endothelial glycocalyx regulates neutrophil adhesion and lung injury during experimental sepsis. Nat Med. 2012 Aug;18(8):1217–23. doi:10.1038/nm.2843.
   PubMed Web of Science ®Google Scholar
• Dogné S, Flamion B. Endothelial glycocalyx impairment in disease: focus on hyaluronan shedding. Am J Pathol. 2020 Apr;190(4):768–80. doi:10.1016/j.ajpath.2019.11.016.
   PubMed Web of Science ®Google Scholar
• Miranda S, Billoir P, Le Besnerais M, Joannides R, Richard V, Lévesque H, Armengol G, Bellien J, Benhamou Y. New insights into antiphospholipid-related endothelial dysfunction by assessment of vascular glycocalyx layer: results from a preliminary cross-sectional study. Lupus. 2020 Feb;29(2):157–64. doi:10.1177/0961203319897958.
   PubMed Web of Science ®Google Scholar
• Kim KJ, Kim JY, Baek IW, Kim WU, Cho CS. Elevated serum levels of syndecan-1 are associated with renal involvement in patients with systemic lupus erythematosus. J Rheumatol. 2015 Feb;42(2):202–09. doi:10.3899/jrheum.140568.
   PubMed Web of Science ®Google Scholar
• He G, Gao Y, Feng L, He G, Wu Q, Gao W, Lin L, Wang W. Correlation between wall shear stress and acute degradation of the endothelial glycocalyx during cardiopulmonary bypass. J Cardiovasc Transl Res. 2020 Dec;13(6):1024–32. doi:10.1007/s12265-020-10027-2.
   PubMed Web of Science ®Google Scholar
• Koo A, Dewey CF Jr, García-Cardeña G. Hemodynamic shear stress characteristic of atherosclerosis-resistant regions promotes glycocalyx formation in cultured endothelial cells. Am J Physiol Cell Physiol. 2013 Jan 15;304(2):C137–46. doi:10.1152/ajpcell.00187.2012.
   PubMed Web of Science ®Google Scholar
• Fukai N, Kenagy RD, Chen L, Gao L, Daum G, Clowes AW. Syndecan-1: an inhibitor of arterial smooth muscle cell growth and intimal hyperplasia. Arterioscler Thromb Vasc Biol. 2009 Sep;29(9):1356–62. doi:10.1161/ATVBAHA.109.190132.
   PubMed Web of Science ®Google Scholar